LONDON, March 26, 2014 /PRNewswire/ --
On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, while the same has fallen by 1.64% in the last one month. Investor-Edge has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on BCRX, SPPI, BMRN, and VRTX can be downloaded upon signing up at:
Shares in BioCryst Pharmaceuticals Inc. closed at $10.02 on Tuesday, which is 1.38% lower than the previous day's closing price of $10.16. A total of 0.39 million shares were traded as compared with three months average volume of 1.26 million shares. The company's shares oscillated between $9.89 and $10.52 during the trading session. Shares in BioCryst Pharmaceuticals Inc. have declined 21.90% in the last one month, while the same has rallied 34.32% in the previous three months and 31.84% on YTD basis. The stock is trading above its 200-day moving average. BioCryst Pharmaceuticals Inc.'s 50-day moving average of $10.92 is above the 200-day moving average of $6.78. Furthermore, the stock is trading at a Relative Strength Index (RSI) of 41.60. Sign up today to read free research on BCRX at:
Spectrum Pharmaceuticals Inc.'s stock witnessed trading of 0.87 million shares on Tuesday, which is below the three months average volume of 0.89 million shares. The stock ended the day at $7.72, down 0.77%, after trading between $7.56 and $7.91 during the session. Shares in Spectrum Pharmaceuticals Inc. have lost 10.44% in the last one month and 12.77% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Spectrum Pharmaceuticals Inc.'s 50-day moving average of $8.52 is above the 200-day moving average of $8.47. Additionally, shares of the company are trading at an RSI of 39.62. Sign up today to read free research on SPPI at:
On Tuesday, BioMarin Pharmaceutical Inc.'s stock declined 2.25% finishing the session at $72.05. The stock recorded a trading volume of 3.21 million shares which is above the three months average volume of 1.29 million shares. The company's shares fluctuated between $68.91 and $74.51 during the session. Shares in BioMarin Pharmaceutical Inc. have fallen by 12.33% in the last one month, while the same has gained 4.12% in the previous three months and 2.42% on YTD basis. The stock is trading above its 200-day moving average. BioMarin Pharmaceutical Inc.'s 50-day moving average of $74.72 is above the 200-day moving average of $68.28. Moreover, shares of the company are trading at an RSI of 40.29. Sign up today to read free research on BMRN at:
Vertex Pharmaceuticals Inc.'s stock recorded a trading volume of 1.41 million shares, as compared with a three month average volume of 1.50 million shares. The stock ended Tuesday's session at $71.90, down 0.75% after vacillating between $70.31 and $73.92. Shares in Vertex Pharmaceuticals Inc. have lost 15.03% in the last one month and 3.23% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Vertex Pharmaceuticals Inc.'s 50-day moving average of $80.61 is above the 200-day moving average of $76.52. Further, the company's shares are trading at a PE ratio of 366.23 and at an RSI of 29.70. Sign up today to read free research on VRTX at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.